Novavax, Inc. (NVAX) Financials

NVAX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 955.6 million 1.1 billion
March 31, 2026 1.0 billion 1.2 billion
Dec. 31, 2025 1.2 billion 1.3 billion
Sept. 30, 2025 1.2 billion 1.3 billion

NVAX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -74.1 million 8.1 million
March 31, 2026 -33.7 million 7.7 million
Dec. 31, 2025 -41.6 million 8.0 million
Sept. 30, 2025 105.8 million 8.5 million

NVAX Net Income

No data available :(

NVAX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 719.3 million 289.8 million 5.8 million
March 31, 2026 790.3 million 291.0 million 4.0 million
Dec. 31, 2025 735.1 million 244.2 million 4.6 million
Sept. 30, 2025 762.9 million 243.8 million 7.3 million

NVAX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 164.6 million
March 31, 2026 163.3 million
Dec. 31, 2025 173.1 million
Sept. 30, 2025 162.4 million

NVAX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 1.3 million 70.7 million 26.7 million -
March 31, 2026 1.3 million 95.5 million 28.8 million -
Dec. 31, 2025 2.1 million 74.0 million 26.9 million -
Sept. 30, 2025 2.0 million 98.3 million 31.7 million -

NVAX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 56.7 million 14.2 million
March 31, 2026 139.5 million 30.7 million
Dec. 31, 2025 147.1 million 25.2 million
Sept. 30, 2025 70.4 million 21.5 million

NVAX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

NVAX

Price: $8.05

52 week price:
6.20
11.97

Earnings Per Share: -1.53 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 6.6 million

Ebitda: -37.6 million

Market Capitalization: 1.3 billion

Links: